. Author manuscript; available in PMC: 2015 Jul 29.

Published in final edited form as: Oncogene. 2014 Mar 17;34(5):537–545. doi: 10.1038/onc.2014.14

Table 2.

Aurora kinase inhibitors

TARGET	MOLECULE	PRECLINICAL ACTIVITY	CLINICAL DEVELOPMENT	REFERENCES
AURORA A	MLN8237/MLN-8054	Leukemia and solid tumors	Phase II	111, 121, 128, 140–145
	MK-5108	Solid tumors	Phase I	128
AURORA B
	AZD1152	Leukemia and solid tumors	Phase II	54, 147–153
	PHA-739358	Leukemia and solid tumor	Phase II	128, 146
AURORA A AND B
	VX-680/MK-0457	Leukemia and solid tumors	Terminated due to toxicity	129, 131–133
	AT9283	Leukemia and solid tumors	Phase II	130, 134–136
	MSC1992371A	Leukemia and solid tumors	Phase I	137–139
	PF-03814735	Solid tumors	Phase I	128
	AS703569	Leukemia and solid tumor	Phase I	128